Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesLumos Diagnostics Holdings Ltd

Lumos Diagnostics Holdings Ltd

Healthcare Medical Devices
PortfolioPortfolio WatchlistWatchlist
Company price
0.06 AUD 0.00(0%)
Last update at 2026-11-06T05:10:00Z
VOLUME
48653
Market Cap
59.29M

Momentum Score

…

Lumos Diagnostics Holdings Limited develops, manufactures, and distributes diagnostic technologies in the United States. The company offers FebriDx, a point-of-care diagnostic test for acute respiratory infections, and ViraDx, a three-in-one point-of-care test for influenza A, influenza B, and COVID-19. It also provides assay development and manufacturing services for point-of-care tests and proprietary digital reader platforms. The company was incorporated in 2018 and is headquartered in Carlsbad, California.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.06
Low
0.06
High
52 Week Price Range
0.06
Low
0.33
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Lumos Diagnostics Holdings Ltd is an Australian company developing molecular point-of-care diagnostic tests and an integrated testing platform for respiratory and infectious diseases. Long-term growth drivers include increasing demand for rapid decentralised testing, broader adoption of point-of-care diagnostics in healthcare settings, and potential expansion into international markets. Investors may find the company attractive for exposure to a technology-led diagnostics franchise that could support recurring test volumes as testing moves closer to patients.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.06
Dividend Yield
-
Revenue TTM
13.19M
Revenue Per Share
0.02
Gross Profit TTM
7.88M
Debt / Equity
0.26
ROE
-34.13%
Net Debt
-9.48M
ROCE
-52.08%
Diluted EPS TTM
-0.01

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -5.57M -7.18M -8.59M -8.97M -45.72M
Net income -5.06M -7.18M -8.59M -8.97M -45.72M
Selling general administrative 18.02M 11.99M 10.45M 10.22M 16.86M
Selling and marketing expenses - 0.50M 0.29M - 2.27M
Gross profit -7.91M 7.91M 7.10M 5.97M 4.46M
Reconciled depreciation 2.55M 2.53M 2.65M 3.67M 2.82M
Ebit -14.44M -7.16M -8.09M -10.24M -21.49M
Ebitda -11.84M -4.63M -5.44M -4.93M -18.67M
Depreciation and amortization 2.60M 2.53M 2.65M - 2.82M
Operating income -14.44M -7.84M -7.12M -9.53M -21.49M
Other operating expenses 27.92M 20.34M 18.25M - 32.70M
Interest expense 2.09M 0.02M 0.97M 0.37M 0.17M
Tax provision 0.00M 0.00M 0.00M 0.00M 0.00M
Interest income 0.05M 0.06M 0.04M 0.02M 0.61M
Net interest income -1.99M -0.53M -1.07M -0.79M -0.61M
Income tax expense -0.51M - -0.96M - 0.19M
Total revenue 13.48M 12.50M 11.13M 10.54M 11.63M
Total operating expenses 6.53M 15.75M 14.22M - 25.53M
Cost of revenue 21.39M 4.59M 4.03M 4.56M 7.17M
Total other income expense net 8.87M 0.66M -1.47M 1.35M -24.04M
Net income from continuing ops -4.95M -7.18M -8.59M -8.97M -45.72M
Net income applicable to common shares - -7.18M -8.59M -8.97M -45.72M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 40.74M 20.81M 26.84M 25.42M 36.94M
Intangible assets 13.49M 8.18M 9.69M 10.89M 12.53M
Other current assets 0.52M 2.32M 1.01M - 1.05M
Total liab 17.88M 14.65M 19.73M 15.92M 19.05M
Total stockholder equity 22.85M 6.16M 7.11M 9.50M 17.89M
Deferred long term liab - - - 7.19M 8.15M
Other current liab 2.93M 3.07M 12.08M 3.46M 10.41M
Common stock 123.07M - 98.23M 92.47M 92.14M
Capital stock 123.13M 103.96M - 92.47M 92.14M
Retained earnings -102.71M -97.84M -90.86M -82.29M -74.53M
Good will - - - - 0.00M
Other assets - - - 7.19M 8.15M
Cash 15.42M 1.96M 6.48M 3.02M 7.98M
Cash and equivalents - - - - 7.98M
Total current liabilities 13.01M 8.71M 12.62M 8.17M 12.83M
Current deferred revenue 6.84M - - - 3.75M
Net debt -9.48M - -6.48M - -0.78M
Short term debt 1.06M - - - 0.97M
Short long term debt - - - 1.35M -
Short long term debt total 5.94M - - - 7.19M
Other stockholder equity - - - -0.68M 0.28M
Property plant equipment - - - 8.56M 10.97M
Total current assets 19.80M 6.46M 9.56M 5.96M 13.44M
Net tangible assets - - - 5.80M 13.50M
Net receivables 2.22M 1.04M 0.67M 1.49M 1.89M
Inventory 1.64M 0.52M 0.78M 1.06M 2.53M
Accounts payable 2.18M 1.37M 0.55M 1.14M 1.45M
Accumulated other comprehensive income 2.49M - -0.26M - 0.28M
Non current assets total 20.94M 14.35M 17.28M 19.45M 23.50M
Capital lease obligations 5.94M 6.99M - 8.44M 7.19M
Long term debt total - - - - 6.23M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -0.05M -0.10M 4.31M -4.36M
Change to liabilities - - - -6.18M -3.10M
Total cashflows from investing activities -2.59M -0.05M -0.10M 4.31M -4.36M
Net borrowings 0.00M - -1.11M 0.79M -1.21M
Total cash from financing activities 15.56M 5.28M 2.63M 0.65M -10.92M
Change to operating activities - - - 0.50M 1.54M
Net income -5.06M -7.18M -8.59M -8.97M -45.72M
Change in cash 13.36M -4.52M 3.46M -4.96M -36.91M
Begin period cash flow 2.07M 6.48M 3.02M 7.98M 44.89M
End period cash flow 15.42M 1.96M 6.48M 3.02M 7.98M
Total cash from operating activities 1.04M -9.33M 0.95M -9.64M -18.04M
Issuance of capital stock 16.27M 6.22M 5.00M - 7.87M
Depreciation 2.60M - 3.15M 3.03M 2.42M
Other cashflows from investing activities - - -0.05M - -
Change to inventory -1.04M 0.26M 0.28M 0.81M -1.35M
Change to account receivables 1.17M -0.37M 0.81M 0.93M -0.18M
Sale purchase of stock - 6.22M 5.00M - -9.71M
Other cashflows from financing activities -1.07M - -1.26M -0.13M -18.79M
Change to netincome - - - -0.74M 27.95M
Capital expenditures 2.59M 0.05M 0.10M 0.12M 4.36M
Change in working capital 4.60M -1.47M 0.05M - 0.02M
Stock based compensation - - 0.45M - -
Other non cash items -1.11M -7.87M 5.89M - -
Free cash flow -1.56M -9.39M 0.85M -9.79M -4.36M

Peer Comparison*

Sector: Healthcare Industry: Medical Devices

Stock Name
Change
(AUD)
Price
(AUD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
LDX
Lumos Diagnostics Holdings Ltd		 -
-%		 0.06 - - 4.49 1.76 2.33 -0.33
COH
Cochlear Ltd		 1.03
0.67%		 155.47 68.64 27.40 4.30 5.34 3.97 28.09
IMR
Imricor Medical Systems Inc		 -0.03
2.29%		 1.28 - - 36401.21 17.45 4019.33 -2.60
AVR
Anteris Technologies Global Corp		 -0.36
4.21%		 8.20 - - 356.02 2.19 130.34 -5.20
AVH
Avita Medical Inc		 -0.08
1.73%		 4.55 - 9.97 9.59 7.17 6.76 15.37

Profile*

Lumos Diagnostics Holdings Ltd

Lumos Diagnostics Holdings Limited develops, manufactures, and distributes diagnostic technologies in the United States. The company offers FebriDx, a point-of-care diagnostic test for acute respiratory infections, and ViraDx, a three-in-one point-of-care test for influenza A, influenza B, and COVID-19. It also provides assay development and manufacturing services for point-of-care tests and proprietary digital reader platforms. The company was incorporated in 2018 and is headquartered in Carlsbad, California.

2724 Loker Ave West, Carlsbad, CA, United States, 92010

855 586 6739

https://lumosdiagnostics.com

Name Title Year Born
Mr. Samuel Lanyon Exec. Chairman NA
Mr. Douglas Ward Chief Exec. Officer NA
Mr. Barrie Lambert Chief Financial Officer NA
Dr. Sacha Dopheide Ph.D. Chief Technology Officer NA
Ms. Jennifer Christiansen VP of Corp. Marketing & Communications NA
Ms. Sarah Glubka Sr. Director of HR NA
Ms. Annie Bell Sr. Director of Medical Affairs NA
Ms. Sue Hibbeln Sr. Director of Regulatory Affairs NA
Mr. Paul Kase Sr. VP of Commercial Operations NA
Ms. Melanie Jaye Leydin B.Bus, C.A., CA Company Sec. 1973

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.74%

  • Communication Services

    +0.56%

  • Consumer Cyclical

    -0.34%

  • Consumer Defensive

    +0.11%

  • Energy

    +1.33%

  • Financial Services

    -0.26%

  • Healthcare

    +2.54%

  • Industrials

    -0.11%

  • Real Estate

    -0.23%

  • Technology

    +1.91%

  • Utilities

    +1.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…